Almost-Smooth Histograms and Sliding-Window Graph Algorithms

We study algorithms for the sliding-window model, an important variant of the data-stream model, in which the goal is to compute some function of a fixed-length suffix of the stream. We extend the smooth-histogram framework of Braverman and Ostrovsky (FOCS 2007) to almost-smooth functions, which includes all subadditive functions. Specifically, we show that if a subadditive function can be $(1+\epsilon)$-approximated in the insertion-only streaming model, then it can be $(2+\epsilon)$-approximated also in the sliding-window model with space complexity larger by factor $O(\epsilon^{-1}\log w)$, where $w$ is the window size. We demonstrate how our framework yields new approximation algorithms with relatively little effort for a variety of problems that do not admit the smooth-histogram technique. For example, in the frequency-vector model, a symmetric norm is subadditive and thus we obtain a sliding-window $(2+\epsilon)$-approximation algorithm for it. Another example is for streaming matrices, where we derive a new sliding-window $(\sqrt{2}+\epsilon)$-approximation algorithm for Schatten $4$-norm. We then consider graph streams and show that many graph problems are subadditive, including maximum submodular matching, minimum vertex-cover, and maximum $k$-cover, thereby deriving sliding-window $O(1)$-approximation algorithms for them almost for free (using known insertion-only algorithms). Finally, we design for every $d\in (1,2]$ an artificial function, based on the maximum-matching size, whose almost-smoothness parameter is exactly $d$

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis:Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors

Objective: To investigate the efficacy and safety of ixekizumab in patients with active radiographic axial spondyloarthritis (SpA) and prior inadequate response to or intolerance of 1 or 2 tumor necrosis factor inhibitors (TNFi). Methods: In this phase III randomized, double-blind, placebo-controlled trial, adult patients with an inadequate response to or intolerance of 1 or 2 TNFi and an established diagnosis of axial SpA (according to the Assessment of SpondyloArthritis international Society [ASAS] criteria for radiographic axial SpA, with radiographic sacroiliitis defined according to the modified New York criteria and ≥1 feature of SpA) were recruited and randomized 1:1:1 to receive placebo or 80-mg subcutaneous ixekizumab every 2 weeks (IXEQ2W) or 4 weeks (IXEQ4W), with an 80-mg or 160-mg starting dose. The primary end point was 40% improvement in disease activity according to the ASAS criteria (ASAS40) at week 16. Secondary outcomes and safety were also assessed. Results: A total of 316 patients were randomized to receive placebo (n = 104), IXEQ2W (n = 98), or IXEQ4W (n = 114). At week 16, significantly higher proportions of IXEQ2W patients (n = 30 [30.6%]; P = 0.003) or IXEQ4W patients (n = 29 [25.4%]; P = 0.017) had achieved an ASAS40 response versus the placebo group (n = 13 [12.5%]), with statistically significant differences reported as early as week 1 with ixekizumab treatment. Statistically significant improvements in disease activity, function, quality of life, and spinal magnetic resonance imaging–evident inflammation were observed after 16 weeks of ixekizumab treatment versus placebo. Treatment-emergent adverse events (AEs) with ixekizumab treatment were more frequent than with placebo. Serious AEs were similar across treatment arms. One death was reported (IXEQ2W group). Conclusion: Ixekizumab treatment for 16 weeks in patients with active radiographic axial SpA and previous inadequate response to or intolerance of 1 or 2 TNFi yields rapid and significant improvements in the signs and symptoms of radiographic axial SpA versus placebo

Plotting the ending: generic expectation and the uncanny epilogue of Crime and Punishment

This article examines the epilogue of Dostoevskii’s novel Crime and Punishment from the perspective of genre and generic expectation. Considering two generic plots that appear in the novel, the detective plot and the redemption narrative, the author argues that the imagined reader’s generic expectation is both satisfied and thwarted in each case. The author introduces the idea of “generic stasis” to refer to Raskol'nikov’s situation vis-à-vis generic plot in each plot trajectory of the epilogue. In upsetting generic expectation, this state of generic stasis creates an opening that enables the novel’s ending to occur. In this sense, the article argues for the utility of the epilogue’s generic hybridity in resisting narrative pre-determination

The ESC ACCA EAPCI EORP acute coronary syndrome ST-elevation myocardial infarction registry

Aims: The Acute Cardiac Care Association (ACCA)-European Association of Percutaneous Coronary Intervention (EAPCI) Registry on ST-elevation myocardial infarction (STEMI) of the EurObservational programme (EORP) of the European Society of Cardiology (ESC) registry aimed to determine the current state of the use of reperfusion therapy in ESC member and ESC affiliated countries and the adherence to ESC STEMI guidelines in patients with STEMI. Methods and results: Between 1 January 2015 and 31 March 2018, a total of 11 462 patients admitted with an initial diagnosis of STEMI according to the 2012 ESC STEMI guidelines were enrolled. Individual patient data were collected across 196 centres and 29 countries. Among the centres, there were 136 percutaneous coronary intervention centres and 91 with cardiac surgery on-site. The majority of centres (129/196) were part of a STEMI network. The main objective of this study was to describe the demographic, clinical, and angiographic characteristics of patients with STEMI. Other objectives include to assess management patterns and in particular the current use of reperfusion therapies and to evaluate how recommendations of most recent STEMI European guidelines regarding reperfusion therapies and adjunctive pharmacological and non-pharmacological treatments are adopted in clinical practice and how their application can impact on patients' outcomes. Patients will be followed for 1 year after admission. Conclusion: The ESC ACCA-EAPCI EORP ACS STEMI registry is an international registry of care and outcomes of patients hospitalized with STEMI. It will provide insights into the contemporary patient profile, management patterns, and 1-year outcome of patients with STEMI